Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science

Cardiovascular disease is the number one cause of death and disability worldwide. While substantial gains have been made in reducing cardiovascular mortality, future projections suggest that we have reached a nadir and may be at an inflection point, given the rising tide of obesity and diabetes. Eva...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Charles Amir German, Michael David Shapiro
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/c5c0257f13f7446b997641574a3cd497
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c5c0257f13f7446b997641574a3cd497
record_format	dspace
spelling	oai:doaj.org-article:c5c0257f13f7446b997641574a3cd4972021-12-04T16:03:20ZAssessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science10.15420/ecr.2019.181758-37641758-3756https://doaj.org/article/c5c0257f13f7446b997641574a3cd4972020-07-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2019.18https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Cardiovascular disease is the number one cause of death and disability worldwide. While substantial gains have been made in reducing cardiovascular mortality, future projections suggest that we have reached a nadir and may be at an inflection point, given the rising tide of obesity and diabetes. Evaluation and management of plasma lipids is central to the prevention of atherosclerotic cardiovascular disease. Although the standard lipid panel represents a well-established platform to assess risk, this test alone can be insufficient and/or misleading. Advances in our understanding of atherosclerosis have led to the development of lipid-based biomarkers that help to discriminate the risk of cardiovascular disease when it is unclear. While these biomarkers provide novel information, their implementation into clinical medicine remains difficult given discrepancies in the literature, lack of assay standardisation, poor accessibility and high cost. However, additional measures of atherogenic lipoproteins or their surrogates may offer insight beyond the standard lipid panel, providing a more precise assessment of risk and more accurate assessment of lipid-lowering therapy.Charles Amir GermanMichael David ShapiroRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 15, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Charles Amir German Michael David Shapiro Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
description	Cardiovascular disease is the number one cause of death and disability worldwide. While substantial gains have been made in reducing cardiovascular mortality, future projections suggest that we have reached a nadir and may be at an inflection point, given the rising tide of obesity and diabetes. Evaluation and management of plasma lipids is central to the prevention of atherosclerotic cardiovascular disease. Although the standard lipid panel represents a well-established platform to assess risk, this test alone can be insufficient and/or misleading. Advances in our understanding of atherosclerosis have led to the development of lipid-based biomarkers that help to discriminate the risk of cardiovascular disease when it is unclear. While these biomarkers provide novel information, their implementation into clinical medicine remains difficult given discrepancies in the literature, lack of assay standardisation, poor accessibility and high cost. However, additional measures of atherogenic lipoproteins or their surrogates may offer insight beyond the standard lipid panel, providing a more precise assessment of risk and more accurate assessment of lipid-lowering therapy.
format	article
author	Charles Amir German Michael David Shapiro
author_facet	Charles Amir German Michael David Shapiro
author_sort	Charles Amir German
title	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
title_short	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
title_full	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
title_fullStr	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
title_full_unstemmed	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
title_sort	assessing atherosclerotic cardiovascular disease risk with advanced lipid testing: state of the science
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/c5c0257f13f7446b997641574a3cd497
work_keys_str_mv	AT charlesamirgerman assessingatheroscleroticcardiovasculardiseaseriskwithadvancedlipidtestingstateofthescience AT michaeldavidshapiro assessingatheroscleroticcardiovasculardiseaseriskwithadvancedlipidtestingstateofthescience
_version_	1718372758927179776

Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science

Ejemplares similares